Ricciardi R, Rossi B, Nicora M, Sghirlanzoni A, Muratorio A
Institute of Neurological Clinic, University of Pisa, Italy.
J Neurol Neurosurg Psychiatry. 1991 Dec;54(12):1061-2. doi: 10.1136/jnnp.54.12.1061.
The effectiveness of intranasal neostigmine (9.3-13.8 mg) was tested in 20 subjects with myasthenia gravis, classified as Osserman grades 2A and 2B. In all cases the drug produced significant clinical and electromyographic improvement. No side effects were reported during the treatment.
对20例诊断为Osserman 2A和2B级的重症肌无力患者,测试了鼻内给予新斯的明(9.3 - 13.8毫克)的有效性。在所有病例中,该药物均产生了显著的临床和肌电图改善。治疗期间未报告副作用。